{
  "main_header": {
    "sid": 1150827,
    "name": "Aytu Biopharma, Inc.",
    "stock_name": "Aytu Biopharma, Inc.",
    "full_name": "Aytu Biopharma, Inc.",
    "name_url": "stocks-analysis/aytu-biopharma-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "2.24",
    "chg": 0.19,
    "chgp": "9.27%",
    "dir": 1,
    "prev_price": "2.05",
    "mcapval": "14.01",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US0547548588",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "103.24 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/aytu-biopharma-inc-1150827-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Aytu Biopharma, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-aytu-biopharma-inc-technically-bullish-or-bearish-3547528",
        "imagepath": "",
        "date": "2025-09-20 19:57:35",
        "description": "As of 14 August 2025, the technical trend for Aytu Biopharma, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating bullish momentum and weekly Bollinger Bands also showing bullish signals. However, the MACD on a weekly basis is mildly bearish, and the KST is bearish, which tempers the overall bullish outlook. The stock has outperformed the S&P 500 in the past week and month, with returns of 3.04% and 7.73% respectively, but has underperformed over the longer term, particularly in the 3-year and 5-year periods...."
      },
      {
        "title": "Is Aytu Biopharma, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-aytu-biopharma-inc-overvalued-or-undervalued-3543870",
        "imagepath": "",
        "date": "2025-09-20 18:31:14",
        "description": "As of 10 September 2025, the valuation grade for Aytu Biopharma, Inc. moved from expensive to fair. The company is currently fairly valued based on its metrics. The P/E ratio stands at 2, the Price to Book Value is 0.35, and the EV to EBITDA ratio is 2.23, indicating a low valuation relative to earnings and book value.\n\nIn comparison to its peers, Aytu Biopharma has a P/E ratio of 2.4637, while Eiger BioPharmaceuticals, Inc. and Biofrontera, Inc. show negative P/E ratios, suggesting that Aytu is in a better position among its risky counterparts. The company's stock has outperformed the S&P 500 over the past week and month, with returns of 3.04% and 7.73%, respectively, although it has lagged behind the index over the longer term, particularly in the 3-year and 5-year periods...."
      }
    ],
    "total": 7,
    "sid": "1150827",
    "stock_news_url": "https://www.marketsmojo.com/news/aytu-biopharma-inc-1150827"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Aytu Biopharma, Inc. technically bullish or bearish?

2025-09-20 19:57:35

As of 14 August 2025, the technical trend for Aytu Biopharma, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating bullish momentum and weekly Bollinger Bands also showing bullish signals. However, the MACD on a weekly basis is mildly bearish, and the KST is bearish, which tempers the overall bullish outlook. The stock has outperformed the S&P 500 in the past week and month, with returns of 3.04% and 7.73% respectively, but has underperformed over the longer term, particularly in the 3-year and 5-year periods....

Read More

Is Aytu Biopharma, Inc. overvalued or undervalued?

2025-09-20 18:31:14

As of 10 September 2025, the valuation grade for Aytu Biopharma, Inc. moved from expensive to fair. The company is currently fairly valued based on its metrics. The P/E ratio stands at 2, the Price to Book Value is 0.35, and the EV to EBITDA ratio is 2.23, indicating a low valuation relative to earnings and book value. In comparison to its peers, Aytu Biopharma has a P/E ratio of 2.4637, while Eiger BioPharmaceuticals, Inc. and Biofrontera, Inc. show negative P/E ratios, suggesting that Aytu is in a better position among its risky counterparts. The company's stock has outperformed the S&P 500 over the past week and month, with returns of 3.04% and 7.73%, respectively, although it has lagged behind the index over the longer term, particularly in the 3-year and 5-year periods....

Read More

View All News